Trial description:
A multiple parallel cohort, non-randomised, open label, multi-centre phase IIa clinical trial aiming to provide proof of principle efficacy for designated targeted therapies in patients with advanced breast cancer where the targetable mutation is identified through ctDNA screening (Only cohort for Triple Negative Breast Cancer remains open)
Contact name:
Dr Richard Baird
Trial start date:
Tuesday, April 11, 2017
Trial end date:
Thursday, December 31, 2020
Trial tumour type:
Breast
Show on Radiotherapy:
No
